|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1700 K Street, NW |
Address2 | Suite 740 |
| City | Washington |
State | DC |
Zip Code | 20006 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401010854-12
|
||||||||
|
6. House ID# 421710000
|
||||||||
| TYPE OF REPORT | 8. Year | 2021 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Ryne Carney |
Date | 4/20/2021 4:51:53 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Signed letter from the Prevent Cancer Foundation to the House of Representatives and Senate supporting the Multi-Center Early Detection Screening Coverage Act
Signed letter to House and Senate leadership urging, in the next COVID-19 relief package, Congress deploy resources to the Aging Network to help COVID-19 vaccination efforts targeting the most at-risk and the most difficult to reach older adults.
Met with White House Domestic Policy Council to discuss ongoing support for adult vaccinations and infrastructure in the present and post-COVID.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ryne |
Carney |
|
Intern Rep. Ed Perlmutter |
|
Michael |
Ward |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Signed letter to Acting HHS Secretary urging withdrawal of the proposed rule RE: Proposed Rule: Establishment of Safeguards and Program Integrity Requirements for Health and Human Services-Funded Extramural Research Involving Human Fetal Tissue (RIN 0991-AC15)
Signed letter to Administration urging a recission of human fetal tissue research restrictions and policy changes that the Department of Health and Human Services made in 2019, specifically NOT-OD-19-128 and NOT-OD-19-137
Signed Leaders Engaged on Alzheimers Disease letter to FDA urging the agency to exercise regulatory flexibility in its review of aducanumab to treat Alzheimers disease.
Participated in PDUFA VII stakeholder meeting with the FDA
Participated in MDUFA V stakeholder meeting with the FDA
17. House(s) of Congress and Federal agencies Check if None
Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ryne |
Carney |
|
Intern. Rep. Ed Perlmutter |
|
Michael |
Ward |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Signed letter supporting the Administrations proposal to invest $450 billion in Medicaid home and community-based services
Signed letter to Acting HHS Secretary urging the reinstatement of the Special Enrollment Period for Part D and Part D and the Equitable Relief for Premium Part A and Part B, requesting these COVID-19 related flexibilities remain in effect until December 31, 2021.
Signed MAPRx letter to HHS Secretary urging a recission of a policy that would allow plans participating in the Center for Medicaid and Medicaid Innovation (CMMI) Part D Payment Modernization (PDM) Model to circumvent laws related to the six protected classes
Signed Modern Medicaid Alliance letter urging House leadership to enhance federal financing for Medicaid by increasing states Federal Medical Assistance Percentage (FMAP) by a total of at least 12 percentage points
Signed a Partnership for Part D Access letter to HHS Secretary urging a recission of a policy that would allow plans participating in the Center for Medicaid and Medicaid Innovation (CMMI) Part D Payment Modernization (PDM) Model to circumvent laws related to the six protected classes.
Submitted letter to the Administration urging a recission of its proposed Most Favored Nations (MFN) proposed rule (CMS-5528-IFC)
Met with staff in the House of Representatives and the Senate to advocate for an out-of-pocket cap in the Part D program and implement a smoothing mechanism to make cost-sharing payments more predictable.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ryne |
Carney |
|
Intern Rep. Ed Perlmutter |
|
Michael |
Ward |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Signed letter to House and Senate Subcommittee on Labor, HHS, Education, and Related Agencies requested $10 million for the Administration for Community Living engagement of the aging services network to implement falls prevention programs and $4 million for the CDCs National Center for Injury Prevention and Control programming
Signed letter to House and Senate Subcommittee on Labor, HHS, Education, and Related Agencies requesting $560 million for the Brain Research through Advancing Innovative Neurotechnology (BRAIN) Initiative
Signed Friends of AHRQ letter to House and Senate Subcommittee on Labor, HHS, Education, and Related Agencies requesting $500 million for the Agency for Healthcare and Research and Quality (AHRQ)
Signed letter to House and Senate leadership expressing support for the provision in the COVID relief reconciliation bill (section 3108) adopted by the House Energy and Commerce Committee to provide additional funding for Medicaid Home and Community Based Services
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ryne |
Carney |
|
Intern, Rep. Ed Perlmutter |
|
Michael |
Ward |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Signed to the Acting Administrator of the US Small Business Administration requesting an investigation and rescission of federal Paycheck Protection Program funds that went to anti-vaccine organizations
17. House(s) of Congress and Federal agencies Check if None
Small Business Administration (SBA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Ward |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |